Recombinant adeno-associated virus serotype 9 (rAAV2/9) and pseudotype rhesus-10 (rAAV2/rh10) are used for gene delivery, especially into the central nervous system. Both serotypes cross the blood–brain barrier and mediate stable long-term transduction in dividing and nondividing cells. Among possible routes of administration, intracardiac injection holds the potential for widespread vector diffusion associated with a relatively simple approach. In this study adopting the intracardiac route, we compare the cell-specific tropism and transfection efficacy of a panel of engineered rAAV2/9 and rAAV2/rh10 vectors encoding the enhanced green fluorescent protein. We observed transduction in the brain and peripherally, with a predominant neuronal tropism while the various serotypes achieved different expression patterns.
Get full access to this article
View all access options for this article.
References
1.
ChtartoA, BockstaelO, TshibanguT, DewitteO, LevivierM, TenenbaumL. A next step in adeno-associated virus-mediated gene therapy for neurological diseases: Regulation and targeting. Br J Clin Pharmacol, 2013; 76:217–232.
ChakrabartyP, RosarioA, CruzP, SiemienskiZ, Ceballos-DiazC, CrosbyK, et al.Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain. PloS One, 2013; 8:e67680.
BourdenxM, DutheilN, BezardE, DehayB. Systemic gene delivery to the central nervous system using adeno-associated virus. Front Mol Neurosci, 2014; 7:50.
6.
Chansel-DebordeauxL, BourdenxM, DoveroS, GrouthierV, DutheilN, EspanaA, et al.In utero delivery of rAAV2/9 induces neuronal expression of the transgene in the brain: Towards new models of Parkinson's disease. Gene Ther, 2017; 24:801–809.
7.
IidaA, TakinoN, MiyauchiH, ShimazakiK, MuramatsuS. Systemic delivery of tyrosine-mutant AAV vectors results in robust transduction of neurons in adult mice. BioMed Res Int, 2013; 2013:974819.
8.
BourdenxM, DoveroS, EngelnM, BidoS, BastideMF, DutheilN, et al.Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by alpha-synuclein overexpression. Acta Neuropathol Commun, 2015; 3:46.
9.
FedericiT, TaubJS, BaumGR, GraySJ, GriegerJC, MatthewsKA, et al.Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Ther, 2012; 19:852–859.
10.
DuqueS, JoussemetB, RiviereC, MaraisT, DubreilL, DouarAM, et al.Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther, 2009; 17:1187–1196.
11.
KurosakiF, UchiboriR, MatoN, SeharaY, SagaY, UrabeM, et al.Optimization of adeno-associated virus vector-mediated gene transfer to the respiratory tract. Gene Ther, 2017; 24:290–297.
12.
WolfDA, HansonLR, AronovichEL, NanZ, LowWC, FreyWH2nd, et al. Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration. Mol Gen Metab, 2012; 106:131–4.
13.
KasparBK, LladoJ, SherkatN, RothsteinJD, GageFH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science, 2003; 301:839–842.
14.
ZolotukhinS, ByrneBJ, MasonE, ZolotukhinI, PotterM, ChesnutK, et al.Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther, 1999; 6:973–985.
15.
YsselsteinD, DehayB, CostantinoIM, McCabeGP, FroschMP, GeorgeJM, et al.Endosulfine-alpha inhibits membrane-induced alpha-synuclein aggregation and protects against alpha-synuclein neurotoxicity. Acta Neuropathol Commun, 2017; 5:3.
16.
AurnhammerC, HaaseM, MuetherN, HauslM, RauschhuberC, HuberI, et al.Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Human gene therapy methods, 2012; 23:18–28.
17.
BishLT, MorineK, SleeperMM, SanmiguelJ, WuD, GaoG, et al.Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther, 2008; 19(:1359–1368.
18.
WangW, JiaYL, LiYC, JingCQ, GuoX, ShangXF, et al.Impact of different promoters, promoter mutation, and an enhancer on recombinant protein expression in CHO cells. Sci Rep, 2017; 7:10416.
19.
CharronG, DoudnikoffE, LauxA, BerthetA, PorrasG, CanronMH, et al.Endogenous morphine-like compound immunoreactivity increases in parkinsonism. Brain, 2011; 134:2321–38.
20.
AlafuzoffI, IncePG, ArzbergerT, Al-SarrajS, BellJ, BodiI, et al.Staging/typing of Lewy body related alpha-synuclein pathology: A study of the BrainNet Europe Consortium. Acta Neuropathol, 2009; 117:635–652.
21.
ShiaoYH, PalliD, CaporasoNE, AlvordWG, AmorosiA, NesiG, et al.Genetic and immunohistochemical analyses of p53 independently predict regional metastasis of gastric cancers. Cancer Epidemiol Biomarkers Prev, 2000; 9:631–633.
22.
HawthorneAC, XavierSP, OkamotoR, SalvadorSL, AntunesAA, SalataLA. Immunohistochemical, tomographic, and histological study on onlay bone graft remodeling. Part III: Allografts. Clin Oral Implants Res, 2013; 24:1164–1172.
23.
EngelnM, FasanoS, AhmedSH, CadorM, BaekelandtV, BezardE, et al.Levodopa gains psychostimulant-like properties after nigral dopaminergic loss. Ann Neurol, 2013; 74:140–144.
24.
DalkaraD, ByrneLC, LeeT, HoffmannNV, SchafferDV, FlanneryJG. Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Ther, 2012; 19:176–181.
FoustKD, WangX, McGovernVL, BraunL, BevanAK, HaidetAM, et al.Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nature Biotechnol, 2010; 28:271–274.
27.
VandenbergheLH, WilsonJM, GaoG. Tailoring the AAV vector capsid for gene therapy. Gene Ther, 2009; 16:311–319.
28.
NakaiH, MontiniE, FuessS, StormTA, GrompeM, KayMA. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nature Genet, 2003; 34:297–302.
29.
RossiA, SalvettiA. [Integration of AAV vectors and insertional mutagenesis]. Med Sci (Paris), 2016; 32:167–174.
30.
ChandlerRJ, SandsMS, VendittiCP. Recombinant adeno-associated viral integration and genotoxicity: Insights from animal models. Hum Gene Ther, 2017; 28:314–322.
31.
Gil-FarinaI, FronzaR, KaeppelC, Lopez-FrancoE, FerreiraV, D'AvolaD, et al.Recombinant AAV integration is not associated with hepatic genotoxicity in nonhuman primates and patients. Mol Ther, 2016; 24:1100–1105.
LentzTB, GraySJ, SamulskiRJ. Viral vectors for gene delivery to the central nervous system. Neurobiol Dis, 2012; 48:179–188.
34.
VassalliG, BuelerH, DudlerJ, von SegesserLK, KappenbergerL. Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in vivo: A comparative study with adenovirus vectors. International J Cardiol, 2003; 90:229–238.
35.
BalathasanL, BeechJS, MuschelRJ. Ultrasonography-guided intracardiac injection: An improvement for quantitative brain colonization assays. Am J Pathol, 2013; 183:26–34.
36.
HwangSJ, LeeHW, KimHR, SongHJ, LeeDH, LeeH, et al.Overexpression of microRNA-95–3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1. Oncotarget, 2015; 6:20434–20448.
37.
JenkinsDE, HornigYS, OeiY, DusichJ, PurchioT. Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res, 2005; 7:R444–R454.
38.
SudoH, TsujiAB, SugyoA, TakuwaH, MasamotoK, TomitaY, et al.Establishment and evaluation of a new highly metastatic tumor cell line 5a-D-Luc-ZsGreen expressing both luciferase and green fluorescent protein. Int J Oncol, 2016; 48):525–532.
39.
KleinRL, HambyME, GongY, HirkoAC, WangS, HughesJA, et al.Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp Neurol, 2002; 176:66–74.
40.
HadaczekP, EberlingJL, PivirottoP, BringasJ, ForsayethJ, BankiewiczKS. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther, 2010; 18:1458–1461.
41.
ZhongL, LiB, MahCS, GovindasamyL, Agbandje-McKennaM, CooperM, et al.Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA, 2008; 105:7827–7832.
42.
KaussMA, SmithLJ, ZhongL, SrivastavaA, WongKKJr., ChatterjeeS. Enhanced long-term transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2. Hum Gene Ther, 2010; 21: 129–1136.
43.
LiM, JayandharanGR, LiB, LingC, MaW, SrivastavaA, et al.High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. Hum Gene Ther, 2010; 21:1527–1543.
44.
MarkusicDM, HerzogRW, AslanidiGV, HoffmanBE, LiB, LiM, et al.High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol Ther, 2010; 18:2048–2056.
45.
Petrs-SilvaH, DinculescuA, LiQ, DengWT, PangJJ, MinSH, et al.Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther, 2011; 19:293–301.
46.
QiaoC, ZhangW, YuanZ, ShinJH, LiJ, JayandharanGR, et al.Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther, 2010; 21:1343–1348.
47.
QiaoC, YuanZ, LiJ, TangR, LiJ, XiaoX. Single tyrosine mutation in AAV8 and AAV9 capsids is insufficient to enhance gene delivery to skeletal muscle and heart. Hum Gene Ther Methods, 2012; 23:29–37.
